このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

肺門部胆管癌に対する陽子線治療と肝移植の併用療法の評価 (EMPHATIC)

2026年11月6日 更新者:The Christie NHS Foundation Trust

肝門部胆管癌に対する陽子線治療と肝移植の併用療法の評価(陽子線研究における評価委託)

Proton Beam Therapy (PBT) is an advanced radiotherapy technique. There are two National Health Service (NHS) PBT treatment centres in the United Kingdom (UK), in Manchester and London. The NHS is committed to ensuring the best use of this limited resource by investigating which patients will benefit from PBT.

Evaluative Commissioning in Protons (ECIP) is a programme of studies exploring the role of PBT in different types of cancer. The studies are funded by NHS England. ECIP studies are not randomised studies, which means that all eligible patients will be offered PBT. Any eligible patient in the UK can be referred, and accommodation is available for patients who don't live close to a PBT centre.

The main benefit of PBT, compared with standard photon radiotherapy, is the predicted reduction in radiation dose to surrounding healthy tissues. With photon radiotherapy, some radiation passes beyond the target area, affecting healthy tissues and causing side-effects. With PBT, the radiation dose stops within the target area, causing less damage to surrounding tissues, and limiting side effects.

EMPHATIC is a study within the ECIP programme. In EMPHATIC, the investigators are looking to see whether a combination of treatments, including PBT, chemotherapy and a liver transplant, can be used to treat patients with cholangiocarcinoma (bile duct cancer).

EMPHATIC offers patients whose cancer can't be removed with surgery (unresectable) a potentially curative treatment option. There is evidence that liver transplant is a curative treatment option in patients with cholangiocarcinoma. There is a risk that the cancer may grow or spread whilst waiting for a transplant, potentially making patients ineligible. PBT and chemotherapy is thought to be the best way to control the cancer, until a liver transplant can be performed. EMPHATIC will look at how a combination of PBT and chemotherapy, followed by a liver transplant, can be used to curatively treat patients with unresectable cholangiocarcinomas.

調査の概要

詳細な説明

Liver and bile duct resection with lymphadenectomy is the standard of care for patients with hilar cholangiocarcinoma. Unfortunately, resection is only possible in a minority of patients for many reasons including, the extent of cancer or the presence of background primary sclerosing cholangitis (PSC). For patients with a background of PSC, liver transplantation is a potential treatment, and it was recently approved as an indication for a commissioned pilot service evaluation of liver transplantation in the UK.

Until recently, the use of liver transplantation for hilar cholangiocarcinoma was confined to a few centres in the United States. The initial publications from the Mayo Clinic and Nebraska, as well as more recent experience from other centres, support strict selection protocols to identify patients likely to benefit from liver transplantation. In 2000, the initial experience at the Mayo Clinic in which 19 patients enrolled in a pre-transplant neoadjuvant therapy protocol was published. 11 patients underwent subsequent liver transplantation. Of the 8 with long term follow up (median 44 months), only one patient developed cancer recurrence. Similarly, the long-term experience of patients in Nebraska, where 11 patients underwent liver transplantation after neoadjuvant chemoradiotherapy was published in 2002. 5 of the 11 patients were alive and disease free at a median follow up of 7.5 years .

Most recent experience is based on adopting the Mayo protocol. In general, the inclusion criteria define patients with early cancers, with a dominant stricture or tumour less than 3cm. Intra and extrahepatic disease including any site of nodal metastases precluded selection. Controversially, histology or cytology was not considered essential for diagnosis of cholangiocarcinoma by most centres. Elevated Ca 19.9 of >100, Fluorescence In Situ Hybridization (FISH) polysomy 9p21 or tumour mass in the presence of a dominant stricture were considered sufficient for enrolment. Prior (attempts at) trans-peritoneal biopsy was another exclusion criterion based on concerns of increased risk of tumour dissemination. Neoadjuvant therapy involved external beam radiation therapy (EBRT) with concurrent chemotherapy (chemo sensitisation), followed by brachytherapy whenever possible. Patients were then re-staged and remain on systemic chemotherapy until the time of transplant.

A recent review looked at all studies from 2000 until 2019. 20 studies with 428 patients were eligible for analysis. The pooled 1, 3-, and 5-year overall survival rates following liver transplantation without neoadjuvant therapy (n=156) were 71.2%. In patients who had neoadjuvant therapy prior to transplantation (n=272), the survival improved to 82.8% at 1,3 and 5 years respectively.

The cancer recurrence rate was 51.7% in patients who did not receive neoadjuvant therapy compared to 24.1% for patients who had. Only 4 of the 20 studies reported pre-transplant histological confirmation of adenocarcinoma or malignant/suspicious cells on cytology. 98% of liver explants from studies not using neoadjuvant therapy confirmed malignancy, compared to 50.5% in those who had received neoadjuvant therapy. Patients in whom malignancy was not found are presumed to have had complete pathological response to neoadjuvant therapy (approximately 50% following neoadjuvant therapy). Patients with background PSC had better outcomes compared to patients with de novo cancers.

Study Design & development of an evaluative commissioning study within ECIP:

It is not possible to design EMPHATIC, a study for patients with unresectable cholangiocarcinoma, as a randomised controlled trial (RCT), because there is no ethically acceptable control arm. In an RCT, patients in a theoretical control arm would be offered either no transplant, or no neoadjuvant therapy prior to the transplant. Based on the published literature summarised above, the adverse anticipated outcomes of patients in such a control arm would not be considered justified.

Neoadjuvant therapy is required to control the tumour prior to transplant. In the Mayo protocol described above, patients received external beam (chemo)radiotherapy followed by brachytherapy, and thereafter received chemotherapy until the time of transplant. Unfortunately, in the UK, brachytherapy services were not seen as a viable option, and hence the Mayo protocol is not feasible.

There is good scientific rationale that proton beam radiotherapy (PBT) offers the optimal technique for delivering neoadjuvant therapy as it is non-invasive, and spares as much functional liver as possible, compared with alternatives such as photon-EBRT techniques or invasive techniques (e.g. brachytherapy). Compared with photon-EBRT techniques, PBT delivers highly conformal radiotherapy, with a significantly reduced integral body dose, and no exit beam. It is expected to be associated with an improved toxicity profile.

研究の種類

介入

入学 (推定)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • London、イギリス
        • 募集
        • University College London Hospitals NHS Foundation Trust
      • Manchester、イギリス
        • 募集
        • The Christie NHS Foundation Trust

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

17年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

General criteria

  • Age 17 years and over
  • Performance status 0 or 1 (Eastern Cooperative Oncology Group)
  • Suitable for liver transplantation as determined by Multi Disciplinary Team (MDT)
  • Able to tolerate neoadjuvant therapy.
  • A history of primary sclerosing cholangitis (PSC) will be a necessary eligibility criterion at the start of the study. Part-way through recruitment to the study, the eligibility criteria may be broadened, allowing patients with sporadic / non-PSC unresectable cholangiocarcinoma to also be considered. The decision to do this will be taken by the Study Management Group, who will be monitor results closely, following an interim analysis after the first 10 patients. Suitability for Orthotropic Liver Transplant will continue to be confirmed in the regional Hepato Biliary cancer MDT.

Specific criteria

  • Presence of a dominant hilar stricture or mass <3cm on cross-sectional imaging
  • Histologically proven cholangiocarcinoma by brush cytology or biopsy via Endoscopic Retrograde Cholangiopancreatography (ERCP) or Percutaneous Transhepatic Cholangiography (PTC)
  • No metastatic disease, including to regional lymph nodes.

Exclusion Criteria:

General criteria

  • Inability to consent
  • Poor performance status
  • Failed fitness assessment
  • Extrahepatic disease at any stage of presentation, assessment and treatment
  • Prior biliary resection or hilar dissection for attempted resection within the past 12 months
  • Prior malignancy in the last 5 years (excluding early breast, prostate, cervix and non melanoma skin cancers)

Specific criteria

  • Estimated Glomerular Filtration Rate (eGFR) <30
  • Prior radiation to the upper abdomen
  • Uncontrolled infection
  • Duodenal invasion

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Proton Beam Therapy

All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy), and alongside concurrent oral capecitabine 625mg/m2 twice daily on radiation days.

All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy)

All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days

Following chemoradiotherapy (PBT + capecitabine), and whilst on the liver transplant waiting list, patients will be offered up to 6 cycles of standard chemotherapy with cisplatin and gemcitabine.

If still eligible after neoadjuvant treatment (PBT + capecitabine), patients will be added to the liver transplant waiting list.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Common Toxicity Criteria for recording Adverse Events (CTCAE) Grade 3 and above toxicity
時間枠:Up to 90 days post neoadjuvant chemo-radiation.

Incidence of Grade ≥ 3 toxicity using CTCAE (grades 0-5) up to 90 days following completion of neoadjuvant (chemo)-PBT and liver transplant. Higher score indicates worse outcome.

Up to 90 days post neoadjuvant chemo-radiation.
Proportion of patients who undergo a successful liver transplant
時間枠:90 days post transplant.

The proportion of patients who, following neoadjuvant (chemo)-PBT, undergo a successful liver transplant (measured at 90 days post-transplant).

90 days post transplant.

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of patients completing planned radiotherapy
時間枠:Up to 1 year

Number of patients completing planned radiotherapy

Up to 1 year
Incidence of severe treatment related side effects
時間枠:Up to 2 years

Rate of Common Toxicity Criteria for recording Adverse Events (CTCAE) Grade 3 and above toxicity (Grades 0-5). Higher score may mean a worse outcome.

Up to 2 years
1 year post completion of neoadjuvant therapy cancer-related mortality
時間枠:At 1 year

Calculated from date of last PBT treatment and defined as time to death or censoring at 1 year.

At 1 year
1 year post transplant overall survival
時間枠:At 1 year

Calculated from date of liver transplant and defined as time to death or censoring at 1 year.

At 1 year
1 year post transplant graft survival
時間枠:At 1 year

Calculated from date of transplant and defined as time to death or censoring at 1 year.

At 1 year
1 year post listing patient survival
時間枠:At 1 year

Calculated from the date the patient was added to the transplant waiting list and defined as time to death or censoring at 1 year.

At 1 year
Disease free survival from transplant
時間枠:At 1 year

Calculated as time to cancer recurrence or death whichever is earliest, from date of transplant, with censoring at 1 year.

At 1 year
Recurrent cancer within 6 months of transplant
時間枠:Up to 6 months following transplant

Described as local, regional or metastatic disease

Up to 6 months following transplant
Cancer control at time of transplant
時間枠:Up to 2 years

Reported as time to loss of cancer control with censoring at time of transplant

Up to 2 years
Cancer control at time of removal from transplant list
時間枠:Up to 2 years

Reported as time to loss of cancer control with censoring at date of removal from transplant waiting list

Up to 2 years
Transplant complication rates
時間枠:Within 3 months of surgery

Surgical complication rates according to Clavien Dindo scale, measured from grades 1-5, higher grade may mean worse outcome.

Within 3 months of surgery
Patient pathway
時間枠:Up to 2 years

Review of patient pathway deliverability defined as time interval from patient referral to the start of chemo-PBT treatment

Up to 2 years
Time to completion of neoadjuvant chemo-PBT treatment to liver transplant
時間枠:Up to 2 years

Measured in days from last day of PBT to date of transplant

Up to 2 years
Time spent on transplant waiting list
時間枠:Up to 2 years

Measured in weeks from transplant listing date to liver transplant date

Up to 2 years
Referral rates
時間枠:At 6 months, 12 months, 18 months and 24 months following the opening of the study

Review annual referral rates to the study

At 6 months, 12 months, 18 months and 24 months following the opening of the study
Recruitment rates
時間枠:At 6 months, 12 months, 18 months and 24 months following the opening of the study

Number of patients participating in the study

At 6 months, 12 months, 18 months and 24 months following the opening of the study

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Maria Hawkins、University College, London
  • 主任研究者:Douglas Thorburn、The Royal Free NHS Foundation Trust

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年10月3日

一次修了 (推定)

2029年11月1日

研究の完了 (推定)

2029年11月1日

試験登録日

最初に提出

2024年4月25日

QC基準を満たした最初の提出物

2024年5月23日

最初の投稿 (実際)

2024年5月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する